Initial HRCT findings of novel influenza A (H1N1) infection.

Objectives: The aim of our study was to describe the presentation and illustrate the imaging features of chest high-resolution computed tomography (HRCT) of patients with novel influenza A (H1N1) virus infection.

Methods: Data were collected from 163 hospitalized patients between November 2009 and March 2011, who fulfilled the clinical criteria for H1N1 influenza infection and underwent HRCT examinations within 24 hours of admission.

Results: Abnormal findings were observed in 40.

MiRNA synergistic network construction and enrichment analysis for common target genes in small-cell lung cancer.

Background: Small-cell lung cancer (also known as SCLC) is an aggressive form and untreated patients generally die within about 3 months. To obtain further insight into mechanism underlying malignancy with this cancer, an miRNA synergistic regulatory network was constructed and analyzed in the present study.

Method: A miRNA microarray dataset was downloaded from the NCBI GEO database (GSE27435).

[Clinical features of ventilator-associated pneumonia caused by acinetobacter].

Objective: To investigate the clinical features of ventilator-associated pneumonia (VAP) caused by acinetobacter.

Methods: The clinical manifestations of 45 cases with ventilator-associated pneumonia caused by acinetobacter between 1995 and 2002 were analyzed. Bacterial susceptibility of acinetobacter strains was determined by Kerby-Bauer method.

[Treatment of spontaneous metastatic lung cancer with interleukin-12 gene-modified dendritic cells vaccine].

Background & Objective: Although many works have been done in treatment of metastatic lung cancer, effective method is lacked. This study was designed to investigate the treatment of spontaneous metastatic lung cancer by interleukin-12 (IL-12) gene-modified dendritic cells (DC) vaccine.

Methods: The spontaneous metastatic lung cancer model, prepared by injection of the 3LL Lewis lung cancer cells into the footpads of C57BL/6 mice, were treated by subcutaneous vaccination with tumor antigen peptide Mut1-pulsed, IL-12 gene-modified dendritic cells (DC-IL-12/Mut1) derived from the normal bone marrow.